Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo

Integrative Cancer Therapies

Volumn 10, Issue 1, 2011, Pages 58-69

  Sze, Stephen C W ^a   Wong, Kam L ^a   Liu, Wing K ^b   Ng, Tzi B ^b   Wong, Jack H ^b   Cheung, Ho P ^a   Yow, Christine M L ^c   Chu, Ellie S M ^a   Liu, Qing ^a   Hu, Yong M ^a   Tsang, Kam W ^a   Lee, Wai S ^a   Tong, Yao ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Chinese medicine decoction; colon cancer; metastasis and multidrug resistance; proliferation; Tian Xian liquid

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; INTERSTITIAL COLLAGENASE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P21; TIAN XIAN WAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG QUALITY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY CONTROL; REGULATORY MECHANISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION;

ANIMALS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 1; MICE; MICE, NUDE; P-GLYCOPROTEIN; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 79953704228     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410378743     Document Type: Article

References (39)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Hong-Kong-Cancer-Registry. 2006. Hospital authority: cancer statistics. http://www3.ha.org.hk/cancereg/e-canstat2006.pdf. Accessed July 12, 2010.
3. Sun A, Chia JS, Chiang CP, et al. The Chinese herbal medicine Tien-Hsien liquid inhibits cell growth and induces apoptosis in a wide variety of human cancer cells. J Altern Complement Med. 2005;11:245-256. (Pubitemid 40647159)
4. Yao CJ, Yang CM, Chuang SE, et al. Targeting PML-RAR{alpha} and oncogenic signaling pathways by Chinese herbal mixture Tien-Hsien liquid in acute promyelocytic leukemia NB4 cells [published online ahead of print November 23, 2009]. Evid Based Complement Alternat Med. doi:10.1093/ecam/nep165.
5. Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene. 1999;18:4313-4325. (Pubitemid 29392372)
6. Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 2000;5:108-114. (Pubitemid 30238230)
7. Leitner HM, Kachadourian R, Day BJ. Harnessing drug resistance: using ABC transporter proteins to target cancer cells. Biochem Pharmacol. 2007;74:1677-1685. (Pubitemid 350088674)
8. Ho JC, Sze SC, Shen WZ, Liu WK. Mitogenic activity of edible mushroom lectins. Biochim Biophys Acta. 2004;1671:9-17. (Pubitemid 38327124)
9. Davis PK, Ho A, Dowdy SF. Biological methods for cell-cycle synchronization of mammalian cells. Biotechniques. 2001;30:1322-1326, 1328, 1330-1331.
10. Li X, Li JP, Yuan HY, et al. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol. 2007;29:607-617. (Pubitemid 351183141)
11. Wang CF, Duo MJ, Chang EE, Yang JY. Essential and toxic trace elements in the Chinese medicine. J Radioanal Nucl Chem. 1996;211:333-347. (Pubitemid 27165549)
12. Smith AH, Biggs ML, Moore L, et al. Cancer risks from arsenic in drinking water: implications for drinking water standards. Arsenic Expo Health Eff. 1999; 3, 191-199. 416
13. Goyer RA, Liu J, Waalkes MP. Cadmium and cancer of prostate and testis. Biometals. 2004;17:555-558. (Pubitemid 41214267)
14. Steenland K, Boffetta P. Lead and cancer in humans: where are we now? Am J Ind Med. 2000;38:295-299. (Pubitemid 30648761)
15. Boffetta P, Merler E, Vainio H. Carcinogenicity of mercury and mercury-compounds. Scand J Work Environ Health. 1993;19:1-7.
16. Department of Health, HKSAR. 2005. Appendix V: determination of heavy metals. http://www.dh.gov.hk/english/main/main-cm/files/vol1/pdf-e/Appendix-V- Determination-of-Heavy-Metals.pdf. Accessed July 10, 2010.
17. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2003;7:1-93.
18. Hammud HH, Nemer G, Sawma W, et al. Copper-adenine complex, a compound, with multi-biochemical targets and potential anti-cancer effect. Chem Biol Interact. 2008;173:84-96.
19. Fishman P, Bar-Yehuda S, Ohana G, et al. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer. 2000;36:1452-1458. (Pubitemid 30421151)
20. Tatsuzaki J, Taniguchi M, Bastow KF, et al. Anti-tumor agents 255: novel glycyrrhetinic acid-dehydrozingerone conjugates as cytotoxic agents. Bioorg Med Chem. 2007;15:6193-6199. (Pubitemid 47088956)
21. Yu B, Lane ME, Pestell RG, Albanese C, Wadler S. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein. Mol Cell Biol Res Commun. 2000;3:352-359.
22. Kato JY, Matsuoka M, Strom DK, Sherr CJ. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol. 1994;14:2713-2721. (Pubitemid 24108252)
23. Shen G, Xu C, Chen C, Hebbar V, Kong AN. p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol. 2006;57:317-327.
24. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701-704. (Pubitemid 24036020)
25. Hofseth LJ, Robles AI, Yang Q, Wang XW, Hussain SP, Harris C. p53: At the crossroads of molecular carcinogenesis and molecular epidemiology. Chest. 2004;125:83S-85S.
26. Paggi MG, Baldi A, Bonetto F, Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem. 1996;62:418-430. (Pubitemid 26301541)
27. Chytil A, Waltner-Law M, West R, et al. Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes. J Biol Chem. 2004;279:47688-47698. (Pubitemid 39540915)
28. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812-821. (Pubitemid 23163585)
29. Fukami-Kobayashi J, Mitsui Y. Cyclin D1 inhibits cell proliferation through binding to PCNA and cdk2. Exp Cell Res. 1999;246:338-347. (Pubitemid 29393996)
30. Airola K, Karonen T, Vaalamo M, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer. 1999;80:733-743. (Pubitemid 29209836)
31. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000;115:337-344.
32. Gartel AL, Tyner AL. The growth-regulatory role of p21 (WAF1/CIP1). Prog Mol Subcell Biol. 1998;20:43-71.
33. Liu BP, Chong EY, Cheung FW, Duan JA, Che CT, Liu WK. Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells. Biochem Pharmacol. 2005;70:287-299. (Pubitemid 40814410)
34. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
35. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem. 1996;42:858-868.
36. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58. (Pubitemid 37328807)
37. Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res. 2007;55:1-15. (Pubitemid 46108588)
38. Chu ES, Yow CM, Shi M, Ho RJ. Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. Toxicol Lett. 2008;181:7-12.
39. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12:927-941. (Pubitemid 47359135)